Announcements Trials

Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 1 Prostatic Neoplasms 1 Multiple Myeloma 1 Lymphoma 1 Glioblastoma 1

Interventions

Temozolomide 94 Radiotherapy 40 Bevacizumab 40 Lomustine 21 Radiation 18 Surgical Procedures, Operative 10 Carboplatin 9 pembrolizumab 8 Nivolumab 8 Carmustine 8 Irinotecan 7 IL13-PE38 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 Flucytosine 6 Cyclophosphamide 6 ABT-414 6 vocimagene amiretrorepvec 5 depatuxizumab mafodotin 5 Valacyclovir 5 Drug Therapy 5 veledimex 4 sargramostim 4 enzastaurin 4 NVP-BKM120 4 Gemcitabine 4 Dianhydrogalactitol 4 Chlorotoxin 4 Aminolevulinic Acid 4 verubulin 3 selinexor 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Glioblastoma × gallium maltolate × Clear all

NCT06404034 2026-03-04

Expanded Access to Gallium Maltolate (GaM)

Imaging Biometrics, LLC

No longer available

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡